Workflow
Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates
BEAMBeam Therapeutics(BEAM) ZACKS·2024-11-06 17:41

Beam Therapeutics Inc. (BEAM) incurred a loss of 1.17pershareinthethirdquarterof2024,widerthantheZacksConsensusEstimateofalossof1.17 per share in the third quarter of 2024, wider than the Zacks Consensus Estimate of a loss of 1.13. The company had recorded a loss of 1.22pershareintheyear−agoquarter.Totalrevenues,comprisinglicenseandcollaborationrevenues,cameinat1.22 per share in the year-ago quarter.Total revenues, comprising license and collaboration revenues, came in at 14.3 million in the third quarter compared with 17.2millionreportedintheyear−agoperiod.ThetoplinemissedtheZacksConsensusEstimateof17.2 million reported in the year-ago period. The top line missed the Zacks Consensus Estimate of 15 million.Stay up-to-date with all quarterly releases: See ...